| Literature DB >> 36119061 |
Shenji Wu1, Jinqiang Huang1, Yongjuan Li2, Mingquan Lei1, Lu Zhao1, Zhe Liu1.
Abstract
Rainbow trout (Oncorhynchus mykiss) is an important economical cold-water fish worldwide. However, infection with infectious hematopoietic necrosis virus (IHNV) has severely restricted the development of aquaculture and caused huge economic losses. Currently, little is known about the immune defense mechanisms of rainbow trout against IHNV. In this study, we detected the changes of immune parameters over different post-infection periods (6-, 12-, 24-, 48-, 72-, 96-, 120-, and 144 hours post-infection (hpi)), mRNA and miRNA expression profiles under 48 hpi (T48L) compared to control (C48L), and key immune-related genes expression patterns in rainbow trout liver following IHNV challenge through biochemical methods, RNA-seq, and qRT-PCR, and the function of miR-330-y was verified by overexpression and silencing in vitro and in vivo. The results revealed that alkaline phosphatase (AKP), alanine aminotransferase (ALT), catalase (CAT), and total superoxide dismutase (T-SOD) activities, and lysozyme (LZM) content showed significant peaks at 48 hpi, whereas malondialdehyde (MDA) content and aspartate aminotransferase (AST) activity decreased continuously during infection, and acid phosphatase (ACP) activity varied slightly. From RNA-seq, a total of 6844 genes and 86 miRNAs were differentially expressed, and numerous immune-related differentially expressed genes (DEGs) involved in RIG-I-like receptor signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, cytokine-cytokine receptor interaction, and antigen processing and presentation were significantly upregulated in T48Lm group, including IFIH1, DHX58, MAVS, TRAF3, IRF3, IRF7, MX1, TLR3, TLR8, MYD88, NOD1, NOD2, IL-8, CXCR1, CD209, CD83, and TAP1. Integrated analysis identified seven miRNAs (miR-425-x, miR-185-x, miR-338-x, miR-330-y, miR-361-x, miR-505-y, and miR-191-x) that target at least three key immune-related DEGs. Expression analysis showed that IFIH1, DHX58, IRF3, IRF7, MX1, TLR3, TLR8, and MYD88 showed a marked increase after 24 hpi during infection. Further research confirmed TAP1 as one of the targets of miR-330-y, overexpression of miR-330-y with mimics or agomir significantly reduced the expression levels of TAP1, IRF3, and IFN, and the opposite effects were obtained by inhibitor. These results facilitate in-depth understanding of the immune mechanisms in rainbow trout against IHNV.Entities:
Keywords: IHNV; RNA-seq; expression analysis; functional analysis; immune parameters; rainbow trout
Mesh:
Substances:
Year: 2022 PMID: 36119061 PMCID: PMC9479325 DOI: 10.3389/fimmu.2022.970321
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786
Figure 1The changes of immune parameters of liver over different periods after infectious hematopoietic necrosis virus (IHNV) infection. (A) Alkaline phosphatase (AKP). (B) Lysozyme (LZM). (C) Alanine aminotransferase (ALT). (D) Catalase (CAT). (E) Total superoxide dismutase (T-SOD). (F) Malondialdehyde (MDA). (G) Aspartate aminotransferase (AST). (H) Acid phosphatase (ACP). The different lowercase letters above the bars represent significant differences (P < 0.05).
Statistical results of comparison rate between reads and reference genomes.
| Sample name | C48Lm-1 | C48Lm-2 | C48Lm-3 | T48Lm-1 | T48Lm-2 | T48Lm-3 |
|---|---|---|---|---|---|---|
|
| 48,463,260 | 43,263,476 | 46,897,752 | 40,461,658 | 42,338,756 | 42,792,066 |
|
| 48,318,822 | 43,137,724 | 46,763,586 | 40,356,426 | 42,236,284 | 42,659,326 |
|
| 98.21% | 98.26% | 98.12% | 98.19% | 97.46% | 98.08% |
|
| 94.73% | 94.86% | 94.54% | 94.65% | 92.71% | 94.42% |
|
| 51.11% | 51.72% | 51.76% | 50.92% | 51.06% | 50.91% |
|
| 42,301,599 (87.57%) | 37,709,558 (87.43%) | 40,377,718 (86.36%) | 35,375,811 (87.68%) | 37,026,559 (87.68%) | 37,429,569 (87.76%) |
|
| 3,789,757 (7.84%) | 3,556,932 (8.25%) | 3,849,203 (8.23%) | 3,170,602 (7.86%) | 3,344,646 (7.92%) | 3,322,004 (7.79%) |
|
| 38511842 (79.72%) | 34152626 (79.19%) | 36528515 (78.13%) | 32205209 (79.82%) | 33681913 (79.76%) | 34107565 (79.97%) |
Categorization of rainbow trout non-coding and organellar small RNAs.
| Sample name | C48Ls-1 | C48Ls-2 | C48Ls-3 | T48Ls-1 | T48Ls-2 | T48Ls-3 |
|---|---|---|---|---|---|---|
|
| 11,475,475 | 11,492,703 | 13,237,075 | 13,306,417 | 11,707,227 | 10,709,646 |
|
| 11,303,003 | 11,274,169 | 12,994,703 | 13,069,970 | 11,505,876 | 10,543,693 |
|
| 9,675,544 (90.00%) | 9,544,642 | 10,712,341 | 10,820,601 | 9,755,915 | 8,913,177 |
|
| 82,298 | 79,559 | 82,436 | 99,625 | 103,603 | 115,269 |
|
| 8,161,789 (75.92%) | 7,158,595 (68.73%) | 7,891,193 (66.05%) | 8,190,412 (69.11%) | 7,420,354 (69.19%) | 6,308,354 (64.64%) |
|
| 8574 (0.08%) | 8481 (0.08%) | 11,574 (0.10%) | 10,542 (0.09%) | 8588 (0.08%) | 7665 (0.08%) |
|
| 2,047,123 (19.04%) | 2,764,324 (26.54%) | 3,363,854 (28.15%) | 3,044,578 (25.69%) | 2,730,668 (25.46%) | 2,866,051 (29.37%) |
|
| 77,946 (0.72%) | 63,080 (0.61%) | 76,344 (0.64%) | 65,207 (0.55%) | 61,042 (0.57%) | 64,394 (0.66%) |
|
| 20,239 (0.19%) | 17,953 (0.17%) | 25,794 (0.22%) | 26,088 (0.22%) | 21,151 (0.20%) | 21,018 (0.22%) |
|
| 24,276 (0.23%) | 19,540 (0.19%) | 32,231 (0.27%) | 25,768 (0.22%) | 21,064 (0.20%) | 19,317 (0.20%) |
|
| 168,613 (1.57%) | 181,119 (1.74%) | 300,657 (2.52%) | 217,608 (1.84%) | 203,275 (1.90%) | 200,313 (2.05%) |
Expression and annotation of immune-related differentially expressed genes (DEGs) between C48Lm and T48Lm groups.
| Gene | Annotation | C48Lm_FPKM | T48Lm_FPKM | Log2 (FC) | FDR | |
|---|---|---|---|---|---|---|
|
| ||||||
|
| Melanoma differentiation associated gene 5 | 5.77 | 45.82 | 2.99 | 1.32E-102 | |
|
| DEXH (Asp-Glu-X-His) box polypeptide 58 | 0.92 | 188.76 | 7.68 | 8.20E-272 | |
|
| Mitochondrial antiviral signaling | 0.59 | 1.28 | 1.11 | 0.03 | |
|
| TNF receptor-associated factor 3 | 0.36 | 6.05 | 4.06 | 1.12E-39 | |
|
| TRAF associated NF-kappa-B activator | 3.03 | 7.72 | 1.35 | 7.43E-08 | |
|
| Inhibitor of nuclear factor kappa-B kinase subunit epsilon | 1.25 | 19.41 | 3.95 | 4.51E-64 | |
|
| DEAD-box helicase 3 X-linked | 9.88 | 68.99 | 2.80 | 3.44E-72 | |
|
| Interferon regulatory factor 3 | 2.01 | 37.75 | 4.23 | 2.23E-130 | |
|
| Interferon regulatory factor 7 | 0.63 | 38.82 | 5.95 | 5.65E-127 | |
|
| E3 ubiquitin/ISG15 ligase TRIM25 | 8.99 | 40.53 | 2.17 | 2.11E-62 | |
|
| ||||||
|
| Toll-like receptor 3 | 6.41 | 38.44 | 2.58 | 6.59E-82 | |
|
| Toll-like receptor 8 | 0.01 | 0.16 | 3.97 | 2.50×10-3 | |
|
| Myeloid differentiation factor 88 | 2.95 | 13.67 | 2.40 | 2.94E-24 | |
|
| Interleukin-1 receptor-associated kinase 4 | 2.13 | 5.56 | 1.39 | 5.91E-08 | |
|
| Interleukin-1 receptor-associated kinase 1 | 0.89 | 1.97 | 1.14 | 2.26×10-3 | |
|
| ||||||
|
| Nucleotide-binding oligomerization domain protein 1 | 0.79 | 6.35 | 3.01 | 2.44E-47 | |
|
| Nucleotide-binding oligomerization domain protein 2 | 0.36 | 2.53 | 2.82 | 7.36E-20 | |
|
| Receptor-interacting serine-protein kinase 2 | 0.28 | 1.07 | 1.96 | 3.30E-10 | |
|
| Nucleotide-oligomerization domain receptor C3 | 0.63 | 4.77 | 2.91 | 3.38E-40 | |
|
| Nucleotide-oligomerization domain receptor C5 | 0.17 | 7.14 | 5.34 | 8.49E-99 | |
|
| ||||||
|
| Interleukin-8 | 0.25 | 1.40 | 2.48 | 1.50×10-3 | |
|
| C-X-C chemokine ligand 10 | 0.08 | 26.00 | 8.41 | 1.98E-21 | |
|
| C-X-C chemokine ligand 11 | 0.05 | 6.68 | 7.16 | 2.63E-10 | |
|
| C-C chemokine ligand 19 | 0.01 | 11.69 | 13.51 | 7.86E-19 | |
|
| C-X-C chemokine receptor 1 | 0.09 | 1.95 | 4.49 | 1.90E-11 | |
|
| C-C chemokine receptor type 8 | 0.55 | 1.63 | 1.56 | 4.62E-05 | |
|
| C-C chemokine receptor type 9 | 0.47 | 1.53 | 1.69 | 0.03 | |
|
| ||||||
|
| C-type lectin domain family 4 member E | 112.39 | 1937.21 | 4.11 | 2.94E-88 | |
|
| CD83 antigen | 0.15 | 1.53 | 3.38 | 3.01E-09 | |
|
| Antigen peptide transporter 1 | 6.17 | 88.68 | 3.85 | 6.46E-152 | |
|
| Antigen peptide transporter 2 | 0.47 | 31.83 | 6.07 | 4.05E-141 | |
|
| MHC class I alpha chain precursor | 22.11 | 53.61 | 1.28 | 1.48E-19 | |
Figure 3Immune system pathways between C48L and T48L groups. (A) Enrichment information of DEGs in immune system pathways. (B) Enrichment information of targets of DEMs in immune system pathways. (C) Enrichment of key immune-related DEGs in corresponding pathways and interaction of immune system pathways. (D) Protein-protein interaction network of immune-related genes obtained in this study.
Figure 2GO enrichment analysis of DEGs between C48Lm and T48Lm groups.
Figure 4RIG-I like receptor (RLR) and Toll-like receptor (TLR) signaling pathways interaction in signaling against viruses.
Figure 5(A) miRNA-mRNA regulatory network of immune-related DEGs. (B) Subnetwork of immune-related DEGs involved in RLR signaling pathway. (C) Subnetwork of immune-related DEGs involved in TLR signaling pathway.
Representative differentially expressed miRNAs (DEMs) in rainbow trout following infectious hematopoietic necrosis virus (IHNV) challenge.
| miRNA-ID | C48Ls_TPM | T48Ls_TPM | Log2 (FC) |
| Target gene |
|---|---|---|---|---|---|
| miR-425-x | 3.01 | 0.45 | –2.73 | 0.02 |
|
| miR-185-x | 3.06 | 0.12 | –4.65 | 6.95×10-3 |
|
| miR-338-x | 21.14 | 8.27 | –1.35 | 4.07×10-3 |
|
| miR-330-y | 1.65 | 0.01 | –7.36 | 0.01 |
|
| miR-361-x | 6.14 | 0.99 | –2.63 | 0.01 |
|
| miR-505-y | 1.14 | 0.01 | –6.83 | 0.04 |
|
| miR-191-x | 176.81 | 41.16 | –2.10 | 3.96×10-3 |
|
Figure 6Validation of DEGs and DEMs by qRT-PCR. (A) The expression comparison of DEGs and DEMs in RNA-seq and qRT-PCR. Error bars indicate standard deviation. Fold-change of qRT-PCR data represents the ratio of DEGs/DEMs expression values for T48L group vs. C48L group after normalization against β-actin/U6. (B) The Pearson correlation analysis between qRT-PCR and RNA-seq results (R = 0.8959, P < 0.0001). The X-axis represents the Log2 (FC) value from qRT-PCR. The Y-axis indicates the Log2 (FC) value from RNA-seq.
Figure 7The changes in expression levels of key immune-related DEGs involved in RLR and TLR signaling pathways over different periods after IHNV challenge. (A) IFIH1 (MDA5). (B) DHX58 (LGP2). (C) MAVS (IPS-1). (D) TANK. (E) AZI2 (NAP1). (F) DDX3X. (G) TLR3. (H) TLR8. (I) MYD88. (J) IRF3. (K) IRF7. (L) MX1. The different lowercase letters above the bars indicate significant differences (P < 0.05).
Figure 8Functional validation of miR-330-y targeting TAP1 in vitro and in vivo. (A) The TAP1-3′UTR sequence was inserted into the pmriGLO vector to construct the wild-type and mutant dual luciferase reporter plasmids, respectively. (B) The results of dual luciferase reporter assay. (C) miR-330-y, (D) TAP1, (E) IRF3, (F) IFN expression levels in rainbow trout liver cells after transfected with miR-330-y mimics or miR-330 inhibitor. (G) Effects of miR-330-y agomir on expression of miR-330-y, TAP1, IRF3, and IFN in vivo. The different lowercase letters above the bars indicate significant differences (P < 0.05); *P < 0.05, **P < 0.01; ns, represents no significant difference (P > 0.05).